Imprint - Zedira GmbH

News

Co-authored article published in Nature Immunology: Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease

Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira

Discover Our New Catalogue Edition and Dive into the World of Transglutaminases!

Co-authored article: The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie

Co-authored posters at ICDS 2022

Successful ISO9001:2015 recertification

Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)

Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie

Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

All news

Blog

Transglutaminase antibodies and neurological manifestations of gluten sensitivity

DZG Aktuell: Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227

Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible?

Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Tridegin as FXIIIa inhibitor

Microbial transglutaminase: from discovery to market

Tissue transglutaminase inhibitors

Tissue transglutaminase in Alzheimers Disease

Factor XIIIa: novel target for anticoagulation?

Microbial transglutaminase for site-specific protein conjugation

Transglutaminases: current research and applications - future directions

All posts

Events

Tampere Celiac Disease Symposium 2025

Date: 10.09.2025 - 12.09.2025
Location: Tampere, Finland

All events

Phone:		+49 6151 66628-0
Fax:		+49 6151 66628-19
E-mail:		contact@zedira.com

Company register:		Amtsgericht Darmstadt HRB 86081
VAT:		DE255202462

Managing partners:		Dr. Martin Hils Dr. Ralf Pasternack